9706014-9
IPOS
copy.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 213/80, 237/24, 403/04, 401/04, 417/12, A61K 31/455, 31/50 — A1

(11) International Publication Number: WO 97/00863

(43) International Publication Date: 9 January 1997 (09.01.97)

(21) International Application Number: PCT/GB96/01442

(22) International Filing Date: 17 June 1996 (17.06.96)

(30) Priority Data:

9512476.4	20 June 1995 (20.06.95)	GB
9601462.6	25 January 1996 (25.01.96)	GB
9606831.7	30 March 1996 (30.03.96)	GB

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(71) Applicant *(for all designated States except US)*: ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventor; and


(75) Inventor/Applicant *(for US only)*: BREAULT, Gloria, Anne [US/GB]; Zeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: TINSLEY, Rachel, Maria; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(54) Title: AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

(57) Abstract

The invention relates to compounds of formula (I), wherein A is an optionally substituted ring system, provided that the $-CH(R^3)N(R^2)B-R^1$ and $-OR^4$ groups are positioned in a 1,2 relationship to one another on ring carbon atoms and the ring atom positioned ortho to the OR^4 linking group (and therefore in the 3-position relative to the $-CHR^3NR^2-$ linking group) is not substituted; B is an optionally substituted ring system: R^1 is positioned on ring B in a 1,3 or 1,4 relationship with the $-CH(R^3)N(R^2)-$ linking group and is as defined in the specification. R^2 is hydrogen, C_{1-6}alkyl, optionally substituted by hydroxy, cyano or trifluoromethyl, C_{2-6}alkenyl (provided the double bond is not in the 1-position), C_{2-6}alkynyl (provided the triple bond is not in the 1-position), phenylC_{1-3}alkyl or pyridylC_{1-3}alkyl; R^3 is hydrogen, methyl or ethyl; R^4 is optionally substituted: C_{1-6}alkyl, C_{3-7}cycloalkylC_{1-3}alkyl or C_{3-7}cycloalkyl; and N-oxides of $-NR^2$ where chemically possible; and S-oxides of sulphur containing rings where chemically possible; and pharmaceutically acceptable salts and *in vivo* hydrolysable esters and amides thereof. Processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.



(I)